Our Case Studies

Our case studies are real examples of projects we have undertaken for our clients. The description includes the challenge that Hawk Pharma Consulting agreed with the client, the actions we took and of course our shared results. Delivery of outputs against that challenge is crucial and this may give clarity that leads to further next steps. We have outlined what we do, our processes and our ways of working with you however we hope that real world, practical examples are interesting and useful – every project is unique in its challenge, in the actions we take and in what we deliver to drive your success.

Optimisation of a Portfolio of Established Brands

Challenge: The problem with portfolios is that they are looked at as one and this does not reflect the reality. This portfolio was 15 medicines, the majority of which were in one therapy area. As a whole the portfolio was losing volumes year on year, losing revenue and losing margin to an even greater degree…
Repurposed molecule > Go-to-market & launch strategy > Operational structure options

Challenge: This Germany headquartered developer wanted to enter the UK market with a repurposed molecule (new form, new indication). They needed confirmation of the likely pricing window and volume forecast. They wanted advice on go-to-market and launch strategy and also the operational structure options to succeed in this less familiar, non-EU market.
Re-positioning an established “Alternative Brand” (branded-generic)

Challenge: In the UK, NHS advice is to prescribe some products (including drug / device combinations) by brand name when generics exist, so that patient continuity is ensured. With the launch of a new competitor branded-generic, this company’s alternative brand’s positioning was no longer compelling or even valid. We supported the UK affiliate to reposition…
Business Development (BD) – Target Product Profile (TPP) realignment to optimise success

Challenge: The challenges in the BD process include finding the finding the assets that you want, convincing the potential partner that you are right for their asset and making an appropriate offer that is accepted by both the partner’s, and your company’s, Board. To streamline efforts and optimise in-license success it was imperative for this…
Environmental Focus & Sustainability – Building a compelling & compliant strategy & communication

Challenge: All companies feel compelled to talk about environmental focus and there is a danger that this can seem like “green-washing”. The NHS has a goal of becoming carbon net zero by 2040 and it has a focus on respiratory inhalers and gaseous anaesthetics as major contributor to the issue. We needed to develop a…
Feasibility of Nordic launch > Strategies for launch

Challenge: The Nordic affiliate of a European pharma company needed advice on the feasibility of launching two related branded generics (or alternative brands) into the four major Nordic markets. Assuming there was opportunity they sought strategic advice on how to launch most effectively.
New product feasibility, forecasting & P&L > go-to-market & launch strategy

Challenge: A pharma company headquartered in Asia Pacific wanted to assess feasibility, go-to-market and launch strategy for a brand that would be the first licensed medicine to treat an increasingly recognised condition in women’s health in the UK. This would assist their decision making and BD process.
New product launch > Portfolio strategy and positioning

Challenge: The UK affiliate of an international pharma company was launching two new brands and, in doing so, it was creating a portfolio in this therapy area. The new portfolio needed a strategy, positioning and messaging. New and existing brands needed their own story within the overall portfolio communication.
Feasibility of entering the UK market > Go-to-market strategy

Challenge: A well established healthcare company headquartered in mainland Europe wanted to understand the feasibility of entering the UK market and, if viable, the best go-to-market strategy for its range of OTX products in the women’s health space.